{"id":"W2547879229","doi":"10.1182/blood.v126.23.2090.2090","title":"Nilotinib Vs Dasatinib As Second-Line Therapy in Patients with Philadelphia-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) Who Are Resistant or Intolerant to Imatinib: A Cost-Effectiveness Analysis (CEA) Based on Real-World Data","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Nilotinib; Dasatinib; Medicine; Discontinuation; Internal medicine; Imatinib; Imatinib mesylate; Oncology; Myeloid leukemia","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0071591,0.001104838,0.001858791,0.001324997,0.000231735,0.001658558,0.001251101,0.0009970792,0.003276414],"category_scores_gemma":[0.008952074,0.0004757219,0.005827196,0.001106291,0.0004715309,0.001160718,0.001238938,0.001732657,0.0001863698],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004948453,"about_ca_system_score_gemma":0.002235064,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008107125,"about_ca_topic_score_gemma":0.006578117,"domain_scores_codex":[0.9971938,0.002110693,0.0001024611,0.000207017,0.000164259,0.000221744],"domain_scores_gemma":[0.99201,0.006652761,0.0007462379,0.0001263639,0.0002188609,0.0002458247],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","study_design_scores_codex":[0.02332971,0.001581768,0.03344418,0.001532647,0.00854702,0.0003390302,0.0001264828,0.9042235,0.0006079982,0.004193761,0.00131952,0.0207544],"study_design_scores_gemma":[0.006728592,0.01705036,0.01921021,0.0004374624,0.008551696,0.0005168392,0.0003312401,0.9381362,0.0009686954,0.004875094,0.003091742,0.0001018873],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9751675,0.00615328,0.01040357,0.001181986,0.00008387057,0.000787571,0.003196976,0.00004811163,0.002977309],"genre_scores_gemma":[0.9955733,0.0007798229,0.001950191,0.0001554147,0.00001812917,0.0002523388,0.0009005939,0.000005870625,0.0003643152],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008107125,"threshold_uncertainty_score":0.03786141,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05560752891826234,"score_gpt":0.347892726618645,"score_spread":0.2922851977003826,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}